The New England Journal of Medicine May 31, 2001

Effect of carvedilol on survival in severe chronic heart failure

Milton Packer, Andrew J.S. Coats, Michael B. Fowler, Hugo A. Katus, Henry Krum, Paul Mohacsi, Jean L. Rouleau, Michal Tendera, Alain Castaigne, Ellen B. Roecker, Melissa K. Schultz, David L. DeMets

Source: View publication →

Bottom Line

In patients with severe chronic heart failure, the addition of carvedilol to standard therapy safely and significantly reduces the risk of death and hospitalization.

Key Findings

1. Carvedilol significantly reduced the risk of death from any cause by 35% compared to placebo (HR 0.65; 95% CI, 0.52 to 0.81; P=0.00014) [6.2.1].

2. At a median follow-up of 10.4 months, there were 130 deaths in the carvedilol group (12.8% per patient-year) compared to 190 deaths in the placebo group (19.7% per patient-year).

3. Carvedilol reduced the combined risk of death or hospitalization for a cardiovascular reason by 27% (P=0.00002) and for heart failure by 31% (P=0.000004).

4. The trial was terminated early by the data and safety monitoring board because of overwhelming evidence of a mortality benefit.

5. Carvedilol was well tolerated in this severe heart failure population; the rate of permanent withdrawal for adverse events was actually lower in the carvedilol group than in the placebo group.

Study Design

Design

RCT

Double-Blind

Sample

2,289

Patients

Duration

10.4 mo

Median

Setting

21 countries

Population Euvolemic patients with severe chronic heart failure (symptoms at rest or on minimal exertion) and a left ventricular ejection fraction < 25%, already receiving standard heart failure therapy.

Intervention Carvedilol, initiated at 3.125 mg twice daily and titrated up to a target dose of 25 mg twice daily, in addition to standard therapy.

Comparator Matching placebo in addition to standard therapy.

Outcome All-cause mortality.

Study Limitations

• The trial excluded patients requiring intensive care, those with marked fluid retention, and those receiving intravenous positive inotropic drugs or vasodilators, limiting generalizability to acute decompensated states.

• Because the trial was terminated early (median follow-up of 10.4 months), the long-term benefits and risks over several years could not be fully assessed in the primary trial.

• Women and elderly patients (over age 75) were somewhat underrepresented, limiting the statistical power of these specific subgroup analyses.

Clinical Significance

COPERNICUS was a landmark trial that definitively proved beta-blockers are highly efficacious and safe in severe, euvolemic heart failure. Prior to this study, many clinicians feared that the negative inotropic effects of beta-blockers would precipitate worsening failure in patients with rest symptoms. By demonstrating a profound 35% relative risk reduction in mortality, the trial established carvedilol as a cornerstone of guideline-directed medical therapy across the full spectrum of symptomatic heart failure with reduced ejection fraction.

Historical Context

Historically, beta-blockers were strictly contraindicated in heart failure. In the late 1990s, landmark trials like CIBIS-II (bisoprolol) and MERIT-HF (metoprolol succinate) overturned this dogma for mild-to-moderate heart failure, showing significant survival benefits. However, patients with severe heart failure (NYHA Class IV) were largely excluded from these trials, leaving an evidence gap regarding safety and efficacy in the sickest patients. COPERNICUS specifically targeted this high-risk population, conclusively proving that beta-blockade is profoundly beneficial even in severe, advanced heart failure.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Carvedilol is a non-selective beta-blocker that also blocks alpha-1 receptors. Physiologically, why is blocking sympathetic nervous system activity beneficial in severe heart failure, despite the fact that beta-blockers are negative inotropes that can acutely decrease cardiac output?

Key Response

This tests the understanding of neurohormonal adaptation in heart failure. Chronic sympathetic overstimulation causes myocyte toxicity, apoptosis, and detrimental remodeling. Blocking this prevents long-term decline, which outweighs the acute negative inotropic effects, while alpha-1 blockade simultaneously reduces afterload.

Resident

A patient with severe heart failure (LVEF 20 percent, NYHA IV) is admitted for acute decompensation. Based on the COPERNICUS trial and current protocols, how should carvedilol be initiated and titrated, and what clinical parameters must be stable before starting therapy?

Key Response

Residents must recognize that beta-blockers should only be started when the patient is euvolemic and clinically stable, without the need for IV inotropes. Starting doses must be very low, such as 3.125 mg twice daily, and titrated slowly over weeks to avoid precipitating acute decompensation.

Fellow

Given carvedilol combined non-selective beta and alpha-1 receptor blockade, how does its hemodynamic profile and effect on clinical outcomes differ from cardioselective beta-blockers like metoprolol succinate in patients with advanced heart failure and marginal blood pressure?

Key Response

Fellows must weigh carvedilol greater afterload reduction from alpha-1 blockade, which can worsen hypotension, versus its potentially superior anti-remodeling and anti-arrhythmic effects compared to beta-1 selective agents in advanced heart failure phenotypes.

Attending

The COPERNICUS trial fundamentally shifted the paradigm from beta-blockers being strictly contraindicated in severe heart failure to being a pillar of guideline-directed medical therapy. How do you teach trainees to overcome clinical inertia and safely push beta-blocker up-titration in patients with borderline low systolic blood pressures who stand to benefit most?

Key Response

Attendings focus on the art of medicine. Teaching points include accepting asymptomatic hypotension, adjusting other blood pressure-lowering medications like diuretics if the patient is euvolemic, and recognizing that severe heart failure patients gain the largest absolute mortality benefit from optimal beta-blockade.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The COPERNICUS trial was terminated prematurely by the Data and Safety Monitoring Board due to a highly significant mortality benefit. Methodologically, what are the risks of truncating a trial early for benefit regarding the estimation of treatment effect size and the evaluation of long-term adverse events?

Key Response

Early stopping for benefit often leads to an overestimation of the treatment effect, sometimes called a random high, and curtails the collection of long-term safety data. This is a critical concept in clinical trial design and biostatistics when evaluating the true magnitude of an intervention.

Journal Editor

The study protocol required patients to be clinically stable on standard therapy without fluid retention or recent need for IV inotropes before randomization. As a reviewer, how does this specific eligibility criteria threaten the external validity of the findings when applied to the broader, often less stable, real-world NYHA class IV population?

Key Response

Editors look for selection bias. By excluding patients who could not stabilize or who required continuous IV inotropes, the trial technically studied stable severe heart failure. Applying these results to crashing or truly unstable NYHA IV patients is a dangerous extrapolation that reviewers must flag.

Guideline Committee

Based on the robust mortality reduction demonstrated in COPERNICUS, current ACC/AHA and ESC guidelines give carvedilol a Class 1 recommendation for HFrEF. How does the committee balance this older, strictly beta-blocker-focused data with the modern advent of ARNI and SGLT2i therapies when sequencing the initiation of the four pillars of guideline-directed medical therapy in newly diagnosed severe heart failure?

Key Response

This addresses guideline evolution. While COPERNICUS established beta-blockers as a foundational pillar, current guidelines emphasize rapid, simultaneous, or closely sequenced initiation of all four pillars rather than historical step-wise approaches, recognizing the additive benefits established across multiple eras of heart failure trials.

Clinical Landscape

Noteworthy Related Trials

1999

CIBIS-II Trial

n = 2,647 · Lancet

Tested

Bisoprolol

Population

NYHA III-IV heart failure patients

Comparator

Placebo

Endpoint

All-cause mortality

Key result: Bisoprolol significantly reduced all-cause mortality compared to placebo.

1999

MERIT-HF Trial

n = 3,991 · Lancet

Tested

Metoprolol CR/XL

Population

NYHA II-IV heart failure patients with LVEF <= 40%

Comparator

Placebo

Endpoint

All-cause mortality

Key result: Metoprolol CR/XL resulted in a 34 percent reduction in all-cause mortality.

2003

COMET Trial

n = 3,029 · Lancet

Tested

Carvedilol

Population

NYHA II-IV heart failure patients with LVEF <= 35%

Comparator

Metoprolol tartrate

Endpoint

All-cause mortality

Key result: Carvedilol significantly reduced all-cause mortality compared to immediate-release metoprolol tartrate.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis